Add like
Add dislike
Add to saved papers

Selective palliative transcatheter embolization of bony metastases from renal cell carcinoma.

To examine whether transcatheter embolization of bone metastases is an effective palliative option for patients with renal cell carcinoma (RCCa). A retrospective review of 21 patients presenting for palliative embolization of painful RCCa skeletal metastases was performed. Details regarding anatomic sites, procedural details, and embolization materials were collected. The clinical response of the patient was assessed from clinic visits and analgesic use. Thirty separate embolization procedures were used to treat 39 metastatic lesions (18 pelvic, 8 lower extremity, 3 upper extremity, 5 rib/chest well, and 5 vertebral lesions). Five patients underwent more than one embolization. Polyvinyl alcohol was used in all 30 embolization procedures. Additional embolic materials were used in 16 of 30 procedures. A clinical response was achieved at 36 treated sites; the mean duration fo the response was 5.5 months. Selective embolization of bony renal cell carcinoma metastases can provide effective palliation in a patient population which has limited therapeutic options.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app